Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 22;11(3):338.
doi: 10.3390/genes11030338.

Diversity of KIR/HLA Genotypes and Their Association with Psoriasis Vulgaris in the Western Mexican Population

Affiliations

Diversity of KIR/HLA Genotypes and Their Association with Psoriasis Vulgaris in the Western Mexican Population

Omar Graciano-Machuca et al. Genes (Basel). .

Abstract

NK and some T cell functions are regulated by the interaction between KIR and HLA molecules. Several studies have shown an association between activating KIR genes and the development of autoimmune diseases, including psoriasis vulgaris (PsV). Our objective was to determine the association between KIR/HLA genes and genotypes with PsV in the Western mestizo Mexican population. One hundred subjects diagnosed with PsV (SP) and 108 healthy subjects (HS) were genotyped for 14 KIR genes, HLA-Bw4, HLA-C1, and HLA-C2 by PCR-single specific primer (SSP). Positive associations of the KIR3DS1 gene (odds ratio (OR) 1.959, p = 0.021), G11 genotype (OR 19.940, p = 0.008), and KIR3DS1/HLA-ABw4 (OR 2.265, p = 0.009) were found with susceptibility to PsV. In contrast, the G1 genotype (OR 0.448, p = 0.031) and KIR3DL1/HLA-Bw4Ile80 (OR 0.522, p = 0.022) were negatively associated with susceptibility to this disease. These results suggest an implication of the KIR3DS1/HLA-ABw4 genotype in PsV pathology.

Keywords: HLA; HLA-Bw4; KIR; KIR3DS1; psoriasis vulgaris.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; nor in the decision to publish the results.

Figures

Figure 1
Figure 1
Distribution of inhibitory and activating KIR genes in healthy subjects (HS) and subjects with psoriasis vulgaris (SP). * p = 0.047 based on X2 and p’ = 0.282, based on Holm–Bonferroni correction for multiple comparisons.

References

    1. Michalek I.M., Loring B., John S. A systematic review of worldwide epidemiology of psoriasis. J. Eur. Acad. Dermatol. Venereol. 2016;31:205–212. doi: 10.1111/jdv.13854. - DOI - PubMed
    1. Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci. 2019;20:1475. doi: 10.3390/ijms20061475. - DOI - PMC - PubMed
    1. De Masson A., Bouaziz J., Battistella M., Bagot M., Bensussan A. Immunopathologie du psoriasis. Médecine/Sciences. 2016;32:253–259. doi: 10.1051/medsci/20163203009. - DOI - PubMed
    1. Raychaudhuri S.K., Maverakis E., Raychaudhuri S.P. Diagnosis and classification of psoriasis. Autoimmun. Rev. 2014;13:490–495. doi: 10.1016/j.autrev.2014.01.008. - DOI - PubMed
    1. Kamiya K., Kishimoto M., Sugai J., Komine M., Ohtsuki M. Risk Factors for the Development of Psoriasis. Int. J. Mol. Sci. 2019;20:4347. doi: 10.3390/ijms20184347. - DOI - PMC - PubMed

Publication types